

ASX Release

Oventus presentation for the Thorney Sydney Investment Forum

Brisbane, Australia 31st May 2018: Oventus Medical Ltd (ASX: OVN) is pleased to attach a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors this morning at the Thorney Sydney Investment Forum.

In the attached presentation, slide 22 has been updated to correct the half year FY2018 revenue number of \$135.74m which should accurately read \$135.74k.

Further information can be found on our website: <http://oventus.com.au>.

—ENDS—

For more information, please contact:

Mr Neil Anderson, Managing Director and CEO: M: 0403 003 475

Jane Lowe, IR Department: M: 0411 117 774 or jane.lowe@irdepartment.com.au

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nCPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O₂Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*



OVENTUS™

Oventus: Innovators in Sleep Apnoea Treatment

Presentation for Thorney
Investment Forum

May 31st 2018



About Oventus (ASX: OVN)

Oventus is commercialising its O₂Vent™ and associated technologies to treat Obstructive Sleep Apnoea (OSA)

Our titanium, 3D printed airway technology “O₂Vent™” enhances treatment outcomes **for more than 50%** of OSA patients



O₂Vent™ device:
in market

* Refer to OVEN-003 Brisbane clinical trial results, announced 22nd May 2018: <http://oventus.com.au/investors/asx-announcements/>



Our valve technology used in conjunction with the “O₂Vent™” enhances treatment outcomes **for more than 75%*** of OSA patients

Oventus ExVent™ oral PEEP valve: expected in market, Q4CY2018

* Refer to NeuRA Sydney interim trial results, announced 29th May 2018: <http://oventus.com.au/investors/asx-announcements/>

Our valves combined with Oventus Airway Technology - truly bridging the gap between oral appliances and CPAP



O2Vent™ ONEPAP (oro-nasal ePAP) valve: in late stage development

* Refer to NeuRA Sydney interim trial results, announced 29th May 2018: <http://oventus.com.au/investors/asx-announcements/>

A close-up photograph of a man with dark hair and a beard sleeping in a bed. He is wearing a white chin strap device that is secured around his head and under his chin. The device appears to be designed to keep the mouth closed during sleep. He is wearing a blue t-shirt. The background shows a white pillow and a white blanket.

Without the need
for a CPAP mask

How Oventus Airway technology works

The O₂Vent™ technology is the first major innovation in the treatment of sleep apnoea for years

1.

Air goes in through the airway on inhalation and out through the airway on exhalation.

Acts like a “second nose” when patient’s mouth is closed. An open mouth is undesirable when sleeping as an open jaw can cause breathing obstruction in the throat.



2.

Air in on inhalation delivered to throat, air out on exhalation

3.

The device brings the lower jaw forward, making more room for air to go into the patient’s lungs

How Oventus Airway technology works

The O₂Vent™ technology is the first major innovation in the treatment of sleep apnoea for years

4.

The valve that sits here still allows low resistance when breathing in but when breathing out it builds up back pressure which acts like a mini CPAP within the device airway.



5.


Pressure builds up here to stabilise the airway



Obstructive sleep apnoea...
more than just a poor night's sleep

**OSA impacts the way
people breathe when they
are sleeping.**

**Breathing is briefly
interrupted or becomes very
shallow during sleep.**

A light gray world map with several colored location pins: three light blue pins in North America, Europe, and East Asia; one orange pin in Southeast Asia; and one dark blue pin in Australia. The text "Poor sleep has major impacts on health economics" is centered over the map.

Poor sleep has major impacts on health economics

80%

Number of sleep apnoea sufferers understood to be out of care right now

\$26.2
BILLION

Financial losses in Australia between 2016-2017 from inadequate sleep

\$40.1
BILLION

Australia attributed \$40.1 billion to loss of well-being in 2016-2017

The big business of sleep

A photograph of a young couple in bed. The woman on the left is sleeping with her mouth wide open, indicating a breathing issue. The man on the right is looking upwards with a concerned expression. They are lying on a bed with light blue and white striped bedding.

Obstructive Sleep Apnoea (OSA) is a massive market.
It is worth US\$3.8** globally, growing at a CAGR of 15-20%.

** In 2015: Sleep Apnea Diagnostic & Therapeutic Devices Market, Markets and Markets, Table 98.



Only 20% of OSA sufferers
are in care.

Why?

Their inability to tolerate
conventional treatment.



Does this look comfortable to you?



Video: how do sleep physicians feel?



Leading sleep physicians, Lee A. Surkin (left) and David E. McCarty (below, left) discuss how improved oral appliance therapy could be game changing for sleep apnoea patients



A recorded copy of this presentation will be available in the coming days at: www.oventus.com.au/investors

Compelling clinical data

In clinical trials (and in real life) our devices succeeded where others could not.

Oventus Airway Technology:

- Makes mouth guards 30-50% more efficacious,
- Treats over 75% of patients without the need for CPAP, and
- Dramatically reduces CPAP pressures and eliminates the need for masks for the small percentage of patients that need it, which
- Delivers significant competitive advantages for half of the current mouth guard and mask market of \$3.8billion/year, and

The ability to bring more patients into care may well dramatically increase this addressable market



>75%

Patients successfully treated their sleep apnoea without using CPAP



100%

Patients Treated without using a full face mask




100%

Patients experienced significant improvement in snoring using O₂Vent

More patients are achieving success* with minimal intervention

Traditional lower jaw advancement (competitor products)	Oventus O ₂ Vent™	Oventus O ₂ Vent™ + EPAP	Oventus O ₂ Vent™ + Connect
Mandibular advancement splints			
44% ¹ of patients treated successfully	53% ¹ of patients treated successfully	78% ² of patients treated successfully	100% ³ of patients treated successfully

Cumulative Treatment Success Using Oventus treatment Platform (AHI ≤ 10 & >50% RDN)



1. Karen McCloy, Damian Lavery, Julia Moldavtsev, Airway open-airway closed: The effect of mandibular advancement therapy for obstructive sleep apnoea with and without a novel in-built airway. Abstract Submitted ASA Brisbane 2018

2. Victor Lai, Benjamin Tong, Carolin Tran, Andrea Ricciardiello, Michelle Donegan, Nicholas Murray, Jayne Carberry and Danny Eckert Combination therapy with mandibular advancement and expiratory positive airway pressure valves reduces OSA severity. Abstract Submitted ASA Brisbane 2018

3. Amatoury J, Tong B, Nguyen C, Szollosi I, Eckert DJ THE ROLE OF A NOVEL ORAL APPLIANCE THERAPY DEVICE ON PHARYNGEAL PRESSURE SWINGS AND CPAP REQUIREMENTS DURING SLEEP IN OBSTRUCTIVE SLEEP APNEA: A PILOT STUDY. Abstract Supplement ADSM Boston 2017

* Traditional Jaw Advancement mouth guard

* AHI < 10 and 50% reduction

Oventus personalised Sleep Treatment Platform

..set to deliver treatment to **all types** of OSA patients,
significantly reducing the need for CPAP

Oventus
O₂Vent™



In market

Oventus
O₂Vent™ + ExVent™
oral EPAP



Expected to be released in
Q4CY2018

Oventus
O₂Vent™ + ONEPAP™
oral/nasal EPAP



In late stage development

Oventus
O₂Vent™ Connect
CPAP connection




In late stage development

With Oventus' Sleep Treatment Platform, many patients reported a good night's sleep... *for the first time in **decades.***



Distribution agreement with Modern Dental Group... the world's largest distributor of dental prosthetics

MODERN DENTAL GROUP LOCATIONS



Modern Dental is listed on HKSE

Ticker: 3600 | Market cap: \$2.21 b

Has 25% coverage of all dentists in USA
(34,000 dental offices through subsidiary,
Microdental)

Top 3 market share in all major European
countries

Australia's largest dental laboratory network

70+ sales and customer service centres
overseas

Focus on custom-made prostheses

Oventus' range is **the only premium device range** that Modern will sell



Innovative clinical solutions, a great team and exceptional clinical data combine to drive adoption in the **sleep channel**

- Four major Sleep Physician networks and training organisations are working with Team Oventus USA as early adopters of the technology
- Training and education is key to having the sleep channel recognise Oventus Airway Technology as a unique and innovative treatment modality to help physicians help their patients
- These early adopters view Oventus Airway Technology as a bridge between Oral Appliance Therapy and CPAP therapy with the ability to bring more patients into care



Team Oventus USA



Robin Randolph

Accomplished Marketing & Sales executive 30+ years in the Sleep Industry. In—depth North America medical device commercialization experience; product management, clinical education, reimbursement, & sales. Sleep Center operations management experience.



Greg Eaton

Experienced medical device sales executive with 20+ years working within Sleep & Respiratory medical device markets. Possess keen innovative insights in the area of executing sales tactics, sales team development & forecasting. Multi-time recognized Presidents Club Achievement awardee for outstanding sales performance.



Peggy Powers

Experienced clinical educator and authority in the sleep & respiratory industry. Registered Respiratory Therapist 20+ years. Highly skilled in the design and delivery of comprehensive training programs for health care providers. Frequent presenter/educator.



Brian Ueda

Skillful marketing manager with an innate ability to take complex technical ideas and distill them into user-friendly visuals to drive marketing campaigns. Experienced in traditional advertising, marketing, graphic design & film.

Corporate snapshot

Oventus Medical Limited: ASX:OVN

Capital structure

Shares on issue	105.94m
Options	3.56m
Price (31/5/2018)	\$0.36
Market Cap (31/5/2018)	\$38.14m
Cash on hand (31/03/2018)	\$11.89m
Revenue 1H FY2018	\$135.74k



Investment summary

Oventus is driving the most significant change the sleep apnoea market has seen for years

- Oventus Airway Technology and valve accessories set to disrupt a large and growing market
- Recent data shows that over 75% of patients can be treated without the need for CPAP*
- Clinical evidence is further building, supported by ongoing clinical trials
- Ramping up dental channel sales, underpinned by Modern Dental distribution agreement
- Building interest in much larger sleep channel, with early adopters driving for change
- OSA market is massive: \$US 3.8 globally, growing at 15-20% CAGR**, with only 20% of OSA sufferers in care
- Strong institutional investor support and balance sheet

* Refer to NeuRA Sydney interim trial results, announced 29th May 2018: <http://oventus.com.au/investors/asx-announcements>; CPAP machine: Continuous Positive Airway Pressure machine. Examples include by ResMed, Fisher & Paykel, and Phillips Respironics

** In 2015: Sleep Apnea Diagnostic & Therapeutic Devices Market, Markets and Markets, Table 98



“I HAVE USED THE OVENTUS DEVICE FOR 3 YEARS AND IT IS AMAZING.

No snoring and so easy to carry around. Used it right through Europe and did not have to worry about electricity or extra bags. Used a CPAP for 20 years. Now I am so free from all that. I love it!”

Jeanne Marshall

See more at www.oventus.com.au